Request and Response Register

Freedom of Information Request Reference: 10850

Date Received: 17/11/2025

Summary:
For each of the last five calendar years (or the last three years if five is not possible), please provide: The number of patients treated at your hospital for reconstructive or corrective eye surgery due to complications from eye-colour changing procedures carried out abroad. If possible and it does not exceed the cost: Of those cases, please specify how many were linked to: Iris implant surgery, Keratopigmentation, laser depigmentation, or any other cosmetic procedure intended to alter eye colour.

Date of Response: 16/12/2025
View Response: 10850.pdf

Freedom of Information Request Reference: 10849

Date Received: 17/11/2025

Summary:
1. How many patients were treated in total, regardless of diagnosis, with these medicines in the 3 months between 1st July 2025 to the end of September 2025, or latest 3-months for which data are available? Name of medicine 1.1 Abiraterone (Zytiga or generic abiraterone) 1.2 Apalutamide (Erleada) 1.3 Cabazitaxel (Jevtana or generic cabazitaxel) 1.4 Darolutamide (Nubeqa) 1.5 Enzalutamide (Xtandi) 1.6 Talazoparib (Talzenna) 1.7 Docetaxel 1.8 Relugolix (Orgovyx, Ryeqo) 1.9 Olaparib (Lynparza) 2. How many patients were treated with these products specifically for prostate cancer (ICD-10 code = C61) in the 3 months between 1st July 2025 to the end of September 2025, or latest 3-months for which data are available? Name of medicine 2.1 Docetaxel for prostate cancer 2.2 Olaparib (Lynparza) for prostate cancer 2.3 Talazoparib (Talzenna) for prostate cancer 2.4 Relugolix (Orgovyx) for prostate cancer 3. How many patients received their first cycle or first dose of the following products in the 3 months between 1st July 2025 to the end of September 2025, or latest 3-months for which data are available? Name of medicine 3.1 Abiraterone (Zytiga or generic abiraterone) 3.2 Apalutamide (Erleada) 3.3 Cabazitaxel (Jevtana or generic cabazitaxel) 3.4 Darolutamide (Nubeqa) 3.5 Enzalutamide (Xtandi) 4. How many patients were treated with the following combinations in the 3 months between 1st July 2025 to the end of September 2025, or latest 3-months for which data are available? Please give total number of patients and number of patients receiving their first dose or first cycle. Name of medicine 4.1 Darolutamide (Nubeqa) + Docetaxel 4.2 Darolutamide (Nubeqa) 4.3 Olaparib (Lynparza) + Abiraterone 5. How many patients received the following products for non-metastatic hormone sensitive prostate cancer in the 3 months between 1st July 2025 to the end of September 2025, or latest 3-months for which data are available? Name of medicine 5.1 Abiraterone 5.2 Enzalutamide 6. How many patients with high grade epithelial stage III or IV ovarian, fallopian tube or primary peritoneal cancer were treated with platinum chemotherapy between 1st July 2025 and 30th September 2025, or latest 3-month period for which data is available? 7. How many patients with high grade epithelial stage III or IV ovarian, fallopian tube or primary peritoneal cancer received maintenance therapy between 1st July 2025 and 30th September 2025, or latest 3-month period for which data is available? 8. How many patients were treated with olaparib (Lynparza) for the following types of cancer between 1st July 2025 and 30th September 2025, or latest 3-month period for which data is available? ICD-10 codes C50* or D05 C56* or C57* or C79.6 or C79.8 or C48.1 or C48.2 C61* 9. How many patients were treated with olaparib (Lynparza) for the following indications and BlueTeq CDF codes between 1st Jul 2025 and 30th Sep 2025, or latest 3-month period for which data is available?

Date of Response: 12/12/2025
View Response: 10849.pdf

Freedom of Information Request Reference: 10848

Date Received: 14/11/2025

Summary:
Q1. Within your Trust, how many patients in total were admitted as inpatients between July – October 2025 with a primary cause of admission being a chronic obstructive pulmonary disease (COPD) exacerbation (ICD-10: J44.1)? Q2. Of the patients admitted with a primary COPD exacerbation (ICD-10: J44.1) identified in Q1, how many were already prescribed a closed triple therapy* at the point of admission? *Closed triple therapy = Trelegy, Trixeo, or Trimbow (any formulation) *“Already prescribed” means the therapy was documented as active on admission, either from hospital records or patient-reported history. Q3. How many patients in total were prescribed Trixeo for COPD (ICD-10: J44.1) between July – October 2025? How many of these were new to Trixeo*? *New to Trixeo = Patient not prescribed Trixeo in your hospital (inpatient or outpatient) in the past 12 months (Nov 2024 – Oct 2025), and not currently prescribed Trixeo—whether prescribed in hospital or community settings—at the point of admission. Q4. How many patients in total were prescribed Trimbow MDI (for COPD [ICD-10: J44.1]) between July – October 2025? · How many of these were new to Trimbow MDI*? · Of the new Trimbow MDI patients*, what was the split between: · Trimbow MDI 87/5/9 · Trimbow MDI 172/5/9 *New to Trimbow MDI = Patient not prescribed Trimbow MDI in your hospital (inpatient or outpatient) in the past 12 months (Nov 2024 – Oct 2025), and not currently prescribed Trimbow MDI—whether prescribed in hospital or community settings—at the point of admission. Q5. How many patients in total were prescribed Trelegy for COPD (ICD-10: J44.1) between July – October 2025? How many of these were new to Trelegy*? *New to Trelegy = Patient not prescribed Trelegy in your hospital (inpatient or outpatient) in the past 12 months (Nov 2024 – Oct 2025), and not currently prescribed Trelegy—whether prescribed in hospital or community settings—at the point of admission. Q6. How many patients in total were prescribed Trimbow DPI (for COPD [ICD-10: J44.1]) between July – October 2025? How many of these were new to Trimbow DPI*? *New to Trimbow DPI = Patient not prescribed Trimbow DPI in your hospital (inpatient or outpatient) in the past 12 months (Nov 2024 – Oct 2025), and not currently prescribed Trimbow DPI—whether prescribed in hospital or community settings—at the point of admission.

Date of Response: 09/12/2025
View Response: 10848.pdf

Freedom of Information Request Reference: 10847

Date Received: 14/11/2025

Summary:
For your organisation, can you please provide me a list of: Employee/Staff Networks recognised by your organisation. Details of any funding provided to that network by your organisation or external source e.g. charity and how that funding has been spent for the past three financial years, broken down by year where possible. Details of any administrative support provided to the organisation, including a breakdown of time/banding of employee providing said support. Any facility/protected time that the network lead (chair, vice chair etc) gets as part of their role. Details of any executive/senior management responsibility for the network. A copy of the terms of reference/memorandum of understanding/network agreement for each network recognised by your organisation, where this document exists.

Date of Response: 11/12/2025
View Response: 10847.pdf

Freedom of Information Request Reference: 10846

Date Received: 14/11/2025

Summary:
I am writing to ask under the provisions of the Freedom of Information (Scotland) Act 2002 that the Board provides me with the following information on employees: • The average length of service of all current employees expressed as a single figure in years and months • The average length of service of all employees and allocated to 10 year groupings, i.e. up to 10 years, between 10 and 20 years, between 20 and 30 years, between 30 and 40 years, and between 40 and 50 years • The average length of service of all employees according to the protected characteristic of sex, with an average for all men and another for all women [sex as defined by the Supreme Court in April 2025 as biological and binary] • The average length of service of all employees according to the protected characteristic of sex, with an average for all men and an average for all women, and allocated to 10 year groupings, i.e. up to 10 years, between 10 and 20 years, between 20 and 30 years, between 30 and 40 years, and between 40 and 50 years • The average length of service of all employees according to the protected characteristic of sex at the point they leave employment with the Board, with an average for all employees, an average for all men and another average for all women • The average length of service of all employees according to the protected characteristic of ethnicity using these sub-groupings [BME - Mixed or Multiple Ethnic Group, Asian Pakistani, Asian Indian, Asian Bangladeshi, Asian Chinese, Asian Other, African, African Other, Caribbean, Black, Caribbean or Black Other, Arab and Other Ethnic Group - White Minority - White Irish, White Gypsy/Traveller, White Polish and White Other - All Other White British - White English, White Northern Irish, White Welsh and White Other British] • The average length of service of all employees according to the protected characteristic of ethnicity using these 3 sub-groups [BME - Mixed or Multiple Ethnic Group, Asian Pakistani, Asian Indian, Asian Bangladeshi, Asian Chinese, Asian Other, African, African Other, Caribbean, Black, Caribbean or Black Other, Arab and Other Ethnic Group - White Minority - White Irish, White Gypsy/Traveller, White Polish and White Other - All Other White British - White English, White Northern Irish, White Welsh and White Other British], and allocated to 10 year groupings, i.e. up to 10 years, between 10 and 20 years, between 20 and 30 years, between 30 and 40 years, and between 40 and 50 years • The average length of service of all employees according to the protected characteristic of ethnicity at the point they leave employment with the Board, with an average for all employees and average for each of the above three sub-groups • The average length of service of all employees according to the protected characteristic of disability, with an average for all disabled people and another for all other employees not identifying as disabled • The average length of service of all employees according to the protected characteristic of disability, with an average for all disabled people and an average for all employees not identifying as disabled, and allocated to 10 year groupings, i.e. up to 10 years, between 10 and 20 years, between 20 and 30 years, between 30 and 40 years, and between 40 and 50 years • The average length of service of all employees according to the protected characteristic of disability at the point they leave employment with the Board, with an average for all employees, an average for all disabled people and an average for all employees not identifying as disabled.

Date of Response: 11/12/2025
View Response: 10846.pdf

Freedom of Information Request Reference: 10845

Date Received: 14/11/2025

Summary:
Please provide information on whether any doctors who have transferred from a General Medical Services (GMS) practice into employment within NHS Lothian, and who have been employed by NHS Lothian for less than 12 months at the start of their maternity leave, have been awarded or received occupational maternity pay. If available, please include: • The number of such cases, if any. • Any policies, procedures, or guidance that set out the criteria for awarding occupational maternity pay in these circumstances.

Date of Response: 19/12/2025
View Response: 10845.pdf

Freedom of Information Request Reference: 10844

Date Received: 14/11/2025

Summary:
Question One How many patients were treated for Urothelial cancer (any stage) in the past 3 months with the following treatments: Atezolizumab (Tecentriq) Avelumab (Bavencio) Carboplatin single agent or in any other combination Carboplatin with Gemcitabine Carboplatin with Gemcitabine + Avelumab (Bavencio) Carboplatin with Paclitaxel Cisplatin single agent or in any other combination Cisplatin with Gemcitabine Cisplatin with Gemcitabine + Nivolumab (Opdivo) Cisplatin with Gemcitabine + Avelumab (Bavencio) Enfortumab Vedotin + Pembrolizumab (Padcev + Keytruda) Nivolumab (Opdivo) Pembrolizumab (Keytruda) Other active systemic anti-cancer therapy Palliative care only Erdafitinib Question Two How many patients have been treated for metastatic Urothelial cancer in the past 3 months with the following systemic anti-cancer therapies: Carboplatin single agent or in any other combination Carboplatin with Gemcitabine Carboplatin with Gemcitabine + Avelumab (Bavencio) Carboplatin with Paclitaxel Cisplatin single agent or in any other combination Cisplatin with Gemcitabine Cisplatin with Gemcitabine + Avelumab (Bavencio) Question Three Does your trust participate in any ongoing clinical trials for the treatment of urothelial cancer? If so, can you please provide the name of each trial along with the number of patients taking part?

Date of Response: 09/12/2025
View Response: 10844.pdf

Freedom of Information Request Reference: 10843

Date Received: 13/11/2025

Summary:
Please provide responses to the following for the most recent full financial year (April 2024 – March 2025). 1. Who is the person responsible for commissioning pulmonary rehabilitation services within your organisation? Please include their name, job title, and contact email if available. 2. Which provider organisations are currently delivering pulmonary rehabilitation services under contract with your organisation? 3. How many people were referred to pulmonary rehabilitation during the most recent full financial year? 4. Of those referred, how many completed a full pulmonary rehabilitation programme during the same period? 5. For which primary conditions or diagnoses do you refer patients to pulmonary rehabilitation? 6. How many individuals are currently on a waiting list for pulmonary rehabilitation, and what is the average waiting time if available? 7. What types or formats of pulmonary rehabilitation are currently offered (for example, face-to-face, home-based, or digital such as MyCOPD)? 8. What outcome measures are used to evaluate pulmonary rehabilitation services (e.g. CAT score, six-minute walk test)?

Date of Response: 15/12/2025
View Response: 10843.pdf

Freedom of Information Request Reference: 10842

Date Received: 13/11/2025

Summary:
1. In each year since 2020-21, including the current year to date, how many employees at this public body have been suspended with full pay? Where an employee’s suspension covers multiple financial years, please only include the year where they were initially suspended. 2. In relation to Q1, what is the respective salary of these employees? 3. Please provide as much detail as possible on why these employees were suspended. E.g. Disciplinary issues, poor quality of work etc.

Date of Response: 15/12/2025
View Response: 10842.pdf

Freedom of Information Request Reference: 10841

Date Received: 13/11/2025

Summary:
1. Cardiac Catheterisation Laboratories (Cath labs) and their utilisation What is the number of cath labs currently in operation within your organisation and the sites at which they are located. In how many of these cath labs do you perform catheter-based valve interventions? How many days per week are catheter-based valve interventions performed in each of these cath labs? Any available data on utilisation of these facilities (e.g. number of sessions scheduled per week, or average percentage utilisation). 2. Cardiac Theatres (used for cardiac surgery) - What is the number and location of cardiac theatres in operation. What is the total number of heart valve repair or replacement procedures (e.g. TAVI, TEER, sAVR or Bentall procedures) performed in both cath labs and cardiac theatres during the most recent full year for which you hold data. 3. Planning How is the provision or planning of the following procedures managed within your jurisdiction for: - Transcatheter Aortic Valve Implantation (TAVI) - Transcatheter Edge-to-Edge Repair (TEER) Are there any current or planned investments in cardiac catheterisation or cardiac surgical capacity (including infrastructure or workforce)? What is the size of the population which is covered by your cardiac service provision?

Date of Response: 11/12/2025
View Response: 10841.pdf

Freedom of Information Request Reference: 10840

Date Received: 13/11/2025

Summary:
Did NHS Lothian implement the British Transplantation Society COVID 19 Guidelines (Guidance on the management of transplant recipients diagnosed with or suspected of having COVID 19) first published in the spring (24th April) of 2020? If so, what date was the guidance implemented?

Date of Response: 11/12/2025
View Response: 10840.pdf

Freedom of Information Request Reference: 10839

Date Received: 13/11/2025

Summary:
Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of July 2025 and the end of September 2025, or latest 3-month period available? Name of medicine 1.1 Abemaciclib (Verzenios) 1.2 Alpelisib (Piqray) 1.3 Elacestrant (Orserdu) 1.4 Fulvestrant (fulvestrant or Faslodex) 1.5 Inavolisib (Inaqovi) 1.6 Palbociclib (Ibrance) 1.7 Ribociclib (Kisqali) 1.8 Capivasertib (Truqap) 1.9 Talazoparib (Talzenna) 1.10 Olaparib (Lynparza) Q2. How many patients received the following medicines for early breast cancer in the 3 months between the start of July 2025 and the end of September 2025, or latest 3-month period for which data are available? Name of combination or monotherapy 2.1 Abemaciclib (Verzenios) 2.2 Ribociclib (Kisqali) 2.3 Olaparib (Lynparza) Q3. How many patients received the following medicines with curative treatment intent in the 3 months between the start of July 2025 and the end of September 2025, or latest 3-month period for which data are available? Name of combination or monotherapy 3.1 Abemaciclib (Verzenios) 3.2 Ribociclib (Kisqali) Q4. How many patients were treated with the following medicines in combination with fulvestrant in the 3 months between the start of July 2025 and the end of September 2025, or latest 3-month period available? Name of combination or monotherapy 4.1 Abemaciclib (Verzenios) + Fulvestrant (fulvestrant or Faslodex) 4.2 Palbociclib (Ibrance) + Fulvestrant (fulvestrant or Faslodex) 4.3 Ribociclib (Kisqali) + Fulvestrant (fulvestrant or Faslodex) Q5. How many patients were treated specifically for breast cancer in the 3 months between the start of July 2025 and the end of September 2025? Type of breast cancer 5.1 Olaparib - All types of breast cancer 5.2 Olaparib - Locally advanced or metastatic breast cancer 5.3 Talazoparib – All types of breast cancer Q6. How many patients were treated in total with the following products in the 3 months between 1st July 2025 to the end of September 2025, or latest 3-months for which data are available? Name of medicine 6.1 Pertuzumab (Perjeta) 6.2 Pertuzumab with Trastuzumab (Phesgo) 6.3 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, trastuzumab) 6.4 Trastuzumab Deruxtecan (EnHertu) 6.5 Trastuzumab Emtansine (Kadcyla) 6.6 Tucatinib (Tukysa) 6.7 Neratinib (Nerlynx) Q7. How many patients were treated with the following products for a diagnosis of Breast Cancer (ICD-10 codes = C50*, D509) in the 3 months between 1st July 2025 to the end of September 2025, or latest 3-months for which data are available? Name of medicine 7.1 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, trastuzumab) 7.2 Trastuzumab Deruxtecan (EnHertu) Q8. How many patients received the following products with curative treatment intent in the 3 months between the start of July 2025 to the end of September 2025, or latest 3-month period for which data are available? Products 8.1 Pertuzumab (Perjeta) 8.2 Pertuzumab with Trastuzumab (Phesgo) 8.3 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, Trastuzumab) 8.4 Trastuzumab Emtansine (Kadcyla) Q9. How many patients received the following products as part of neoadjuvant or adjuvant therapy in the 3 months between the start of July 2025 to the end of September 2025, or latest 3-month period for which data are available? Products 9.1 Pertuzumab (Perjeta) 9.2 Pertuzumab with Trastuzumab (Phesgo) 9.3 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, trastuzumab) 9.4 Trastuzumab Emtansine (Kadcyla)   Q10. How many patients received trastuzumab deruxtecan (Enhertu) for the following types of breast cancer in the 3 months between the start of July 2025 to the end of September 2025, or latest 3-month period for which data are available? Treatment intent 10.1 HER2+ve Breast Cancer 10.2 HER2-low Breast Cancer Q11. How many patients were treated for the following indications for metastatic HER2+ve breast cancer by product, in the 3 months between 1st July 2025 and 30th September 2025, or latest 3-months for which data are available? Name of medicine Line of Therapy (indication) 11.1 Trastuzumab Deruxtecan (Enhertu) Following one or more prior anti-HER2-based regimens 11.2 Trastuzumab Deruxtecan (Enhertu) Following one prior anti HER2-based regimen 11.3 Trastuzumab Emtansine (Kadcyla) Following one or more prior anti-HER2-based regimens 11.4 Trastuzumab Emtansine (Kadcyla) Following one prior anti HER2-based regimen 11.5 Trastuzumab Following one or more prior anti-HER2-based regimens 11.6 Trastuzumab Following one prior anti HER2-based regimen

Date of Response: 05/12/2025
View Response: 10839.pdf

Freedom of Information Request Reference: 10838

Date Received: 12/11/2025

Summary:
Contract 1 – Wide Area Network (WAN) Services (Including HSCN) 1. WAN Provider(s) Please confirm the main supplier(s) for your WAN services. If this information is not available, please explain why. 2. Contract Expiry Date Please provide the expiry date for each WAN contract (DD/MM/YYYY or MM/YYYY acceptable). If rolling, please state the terms. 3. Contract Description Please provide a brief summary of the scope of each WAN contract. 4. Number of Sites Covered Please indicate the number of sites supported by the WAN. An approximation is acceptable. 5. Annual Average Spend What is the annual average spend for WAN services? Please break this down by provider if more than one. 6. Procurement Route Please provide details of how each WAN contract was procured. If a framework was used, please include the framework name and reference number. ________________________________________ Internal Contact Please provide the full contact details for the person(s) responsible for each of the above contracts, including: • Full name • Job title • Direct phone number • Email address

Date of Response: 05/12/2025
View Response: 10838.pdf

Freedom of Information Request Reference: 10837

Date Received: 12/11/2025

Summary:
How many SAER ( significant adverse event reviews) reviews took place within Edinburgh Royal Infirmary in the last 12 months? Of these SAER's how many resulted in a death? How many SAERs took place in The Royal Edinburgh hospital in the same 12 months and of these how many resulted in a patient death.?

Date of Response: 16/12/2025
View Response: 10837.pdf

Freedom of Information Request Reference: 10836

Date Received: 12/11/2025

Summary:
The information I request is: for each of your surgeons who have performed cataract operations during the past three years, for each of the past three years, the number of cataract operations performed, percent operations with posterior capsule rupture and percent operations with vision loss.

Date of Response: 11/12/2025
View Response: 10836.pdf

Freedom of Information Request Reference: 10835

Date Received: 12/11/2025

Summary:
Please can you confirm the below: • Spend on Insourcing from August 2025-end of October 2025, broken down by each specialty and subspecialty, and the insourcing company that was used, e.g. cardiology £1000- echo cardiogram £1000- company x £1000 • The budget for each specialty for insourcing • Confirm the contract start and end date for each specialty • What frameworks were used for each specialty and was there direct awards and if so, who was they awarded to and what specialty • What was the service, e.g. theatres, outpatient, or diagnostic

Date of Response: 11/12/2025
View Response: 10835.pdf

Freedom of Information Request Reference: 10834

Date Received: 12/11/2025

Summary:
I am unhappy with the Board’s response for a number of reasons and would invite the Board to review the response and attempt to actually answer the questions put. In the Board’s response to the first question, the Board said: Three of the strategic priorities demonstrate how NHS Lothian is giving due regard to the need to foster good relations between people who share the protected characteristic of gender reassignment and those who do not are ………. This is quite simply wrong. I asked for: some or all of the distinct actions and steps aimed at ‘fostering good relations’ between the two cohorts [defined in the preceding paragraph as being between people with the protected characteristic of ‘gender reassignment’ and people who share the protected characteristic of ‘sex’ and who are women]. This renders the Board response as both wrong and irrelevant, and attempting to substitute strategic priorities for ‘distinct actions and steps’. Given this is fundamental to the issues on which information has been asked, I would invite the Board to learn from the mistakes and review and revise the answers to provide distinct actions and steps aimed at ‘fostering good relations’ between the two cohorts [defined as being between people with the protected characteristic of ‘gender reassignment’ and people who share the protected characteristic of ‘sex’ and who are women], both pre- and post-Supreme Court judgement. In addition, I had asked for information on: could you also please let me know what benchmarking, data gathering and other systemic changes were put in place to track the actual impact of ‘fostering good relations’ actions between the two cohorts and what measurable outcomes these showed or produced, pre-Supreme Court judgement ? The Board’s answer was: In January 2025, NHS Lothian started the first annual equality and human rights staff survey. This survey aims to identify staff views about the extent to which NHS Lothian is making progress towards achieving the equality and human rights strategic priorities and staff experiences of discrimination, harassment, bullying and behaviour that is described as microaggressions This is a broad brushstroke answer to a very specific question and will not necessarily provide relevant and/or accurate data on relations between the two cohorts the subject of my original request. It is also only a partial answer as it deals with staff views. The views and experiences of both cohorts as service users appear to have been overlooked/ignored by the Board. In the overall review of the Board’s response I would invite the Board to set out answers which include answers containing data relevant to service users from the two cohorts. Overall, the Board’s response falls considerably short of what was in fact asked and does beg the question of whether those responsible for compiling the response actually understood what was being asked for or indeed understood the contest of the request.

Date of Response: 11/12/2025
View Response: 10834.pdf

Freedom of Information Request Reference: 10833

Date Received: 11/11/2025

Summary:
The questions refer to the time period of 2024-2025. Can you please provide answers to the following questions for your health board area. Workforce 1. The following sub-questions refer to qualified/registered audiologists in your department (please include audiologists and clinical scientists that provide audiological services): a) How many audiologists do you have in headcount? b) How many audiologists do you have in full time equivalents (FTE)? c) How many FTE job vacancies do you have for qualified audiologists/registered audiologists? Services 2. What % of patients referred to adult audiology services for a hearing assessment are referred a) from ENT and b) directly from their GP? 3. How many adult hearing assessments were performed in 2024/25? 4. How many adults were fitted with hearing aids in 2024/25? And how many were new patients? 5. What is the average time a patient waits to receive their hearing aid(s) after referral from their GP? 6. What is the local bilateral fitting rate? (please just state the percentage – i.e. an explanation is not required). 7. After fitting a hearing aid, what are the average wait times for a follow up appointment? 8. How often are patients offered a reassessment? (i.e., how many years after they are fitted are patients recalled for a routine hearing assessment to check their hearing and whether hearing aids need reviewing/replacing) 9. How are follow up care and reassessments delivered e.g., structured and requested from the audiology department or left to patient-initiated follow-up (PIFU)? 10. Please list all locations that provide adult hearing services in your health board area and what services are provided at each location.

Date of Response: 09/12/2025
View Response: 10833.pdf

Freedom of Information Request Reference: 10832

Date Received: 11/11/2025

Summary:
1. Any programme budgeting or internal costing that separately identified endometriosis (ICD - 10 N80) 2. Annual spend on endometriosis diagnosis/treatment (surgery, imaging, outpatient clinics, specialist centre budgets) for the last 5-7 years.

Date of Response: 05/12/2025
View Response: 10832.pdf

Freedom of Information Request Reference: 10831

Date Received: 11/11/2025

Summary:
Q1. How many patients were treated for endometrial cancer (any stage) in the past three months with the following treatments: • Dostarlimab (Jemperli) • Dostarlimab (Jemperli) AND Chemotherapy • Hormone therapy (Progesterone or Letrozole) • Pembrolizumab (Keytruda) monotherapy • Lenvatinib + Pembrolizumab (Lenvima +Keytruda)  • Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide) • Any other SACT • Any other Chemotherapy • Durvalumab with platinum-based chemotherapy • Pembrolizumab with platinum-based chemotherapy Q2. In the past three months, how many patients were treated for endometrial cancer with the following as first line treatments: • Dostarlimab (Jemperli) AND Chemotherapy • Durvalumab with platinum-based chemotherapy • Pembrolizumab with platinum-based chemotherapy • Hormone therapy (Progesterone or Letrozole) • Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide) • Any other SACT • Any other chemotherapy Q3. Does your trust participate in any clinical trials for the treatment of endometrial cancer? If so, can you please provide the name of each trial and the number of patients taking part.

Date of Response: 10/12/2025
View Response: 10831.pdf

Freedom of Information Request Reference: 10830

Date Received: 24/10/2025

Summary:
During our conversations with NHS Facilities we have been advised they do not hold vital information that has led to problems in agreeing our shared understanding and being able to move forward. I attach a NHS document from November 2006 detailing the current arrangement and invoices relating to this. Specifically the long standing reimbursement process set up by NHS Lothian. I would be grateful if you can confirm if you also hold this information.

Date of Response: 19/12/2025
View Response: 10830.pdf

Freedom of Information Request Reference: 10829

Date Received: 11/11/2025

Summary:
In the week beginning 3 November, how much did the NHS spend on food for patients? In the week beginning 3 November 2025, what was the nutritional value of each standard meal provided to patients? In the week beginning 3 November 2025, what was the calorie content of each standard meal provided to patients? In the week beginning 3 November 2025, how many standard patient meals contained ultra processed food?

Date of Response: 10/12/2025
View Response: 10829.pdf

Freedom of Information Request Reference: 10828

Date Received: 10/11/2025

Summary:
Please provide: 1. The number of adult inpatients (aged 18+) in NHS Lothian hospitals in each of the last three financial years (2022/23, 2023/24, and year-to-date 2025) who were recorded as being delayed in hospital discharge due to: o a) Absence of a registered Power of Attorney; and/or o b) A pending or required guardianship order. 2. The average and longest length of delay (in days) for patients where (a) or (b) above was a contributing factor. 3. Any available internal data or assessments regarding the impact of capacity-related discharge delays (e.g., cost to NHS, bed occupancy, or patient outcomes). 4. If available, any policy documents, guidance, or reports produced by NHS Lothian or the relevant Health and Social Care Partnership relating to capacity, guardianship, or Power of Attorney and hospital discharge.

Date of Response: 09/12/2025
View Response: 10828.pdf

Freedom of Information Request Reference: 10826

Date Received: 11/11/2025

Summary:
I was looking for retention data such as but not limited to: • The average length of service [in years and months] of the current workforce • The average length of service of those leaving government employment • The average length of service of each cohort [men and women in the protected characteristic of sex for example] within each of the protected characteristics • The average sickness absence rates alongside the average length of service of each cohort within each of the protected characteristics

Date of Response: 05/12/2025
View Response: 10826.pdf

Freedom of Information Request Reference: 10825

Date Received: 11/11/2025

Summary:
The number individuals diagnosed with mesothelioma in NHS Lothian, by hospital, for the period 2020 to date, broken down by year, if possible.

Date of Response: 11/12/2025
View Response: 10825.pdf

Freedom of Information Request Reference: 10824

Date Received: 11/11/2025

Summary:
1. What proportion of men waiting for bladder outlet surgery were catheterised prior to surgery, in the quarter ending 30th June 2025? 2. What proportion of men undergoing bladder outlet surgery had a urinary catheter when they were admitted for surgery, in the quarter ending June 2025? 3. If a man presents with urinary retention and is catheterised or taught to self-catheterise what is the average time to surgery for these men? 4. What was the average waiting time for men with lower urinary tract symptoms from referral to specialist Urology services to treatment decision, in the quarter ending 30th June 2025? 5. What was the average waiting time for men with lower urinary tract symptoms from treatment decision to surgery, in the quarter ending June 2025?

Date of Response: 05/12/2025
View Response: 10824.pdf

Freedom of Information Request Reference: 10823

Date Received: 11/11/2025

Summary:
1. How many beds in use in hospitals does your Health Board have ? 2. How many beds not in use in Hospitals does your Health Board have? 3 How many hospital beds are in use for Thrombosis related conditions.? 4 How much on average does it cost per day (24 hours)to care for Thrombosis related conditions?

Date of Response: 05/12/2025
View Response: 10823.pdf

Freedom of Information Request Reference: 10822

Date Received: 11/11/2025

Summary:
Please provide the following information for the period 1 January 2015 to the present: 1. The total number of formal complaints, Datix reports, or clinical-governance investigations that named or involved Dr ~~~~~~. 2. For each, whether the outcome was upheld, partially upheld, or dismissed. 3. The broad subject category of each complaint (for example, communication, treatment delay, informed consent, clinical decision-making, or patient-family relations). 4. Any actions, recommendations, or retraining recorded as outcomes of those investigations. 5. Any external reviews, audits, or service evaluations of paediatric oncology in which Dr ~~~~~~ clinical practice or decision-making was specifically discussed or reviewed.

Date of Response: 08/12/2025
View Response: 10822.pdf

Freedom of Information Request Reference: 10821

Date Received: 11/11/2025

Summary:
I must formally advise that the statutory deadline for a substantive response, which your team confirmed was 10 November 2025, has now passed without the information being provided.

Date of Response: 10/12/2025
View Response: 10821.pdf

Freedom of Information Request Reference: 10820

Date Received: 10/11/2025

Summary:
I note that the response you have provided refers to a referral from a GP practice on 12 January 2023 and 16 January 2023. Please can you confirm if the quoted average wait time of around 9 calendar days would have differed in the event an urgent referral was made by the referring GP practice on these two dates?

Date of Response: 11/12/2025
View Response: 10820.pdf

Freedom of Information Request Reference: 10819

Date Received: 10/11/2025

Summary:
Q1. Please provide the total number of patients treated in the last 6 months for: •Polycythaemia Vera (ICD10 code D45) •Myelofibrosis (ICD10 code D47.4) •Myelofibrosis (ICD10 code D47.4) patients aged 65 and older Q2. How many patients were treated in the past 6 months (for any disease) with: •Ruxolitinib •Fedratinib •Momelotinib Q3. How many patients were treated with Ruxolitinib in the past 6 months for the following diseases? •Myelofibrosis (ICD10 code D47.4) •Polycythaemia Vera (ICD10 code D45) •Other/Unknown Q4. How many myelofibrosis (ICD10 code D47.4) patients has your trust diagnosed in the past 3 years? •Of these patients, how many were treated in the past 6 months with Hydroxycarbamide? •Of these patients, how many were treated in the past 6 months with Interferon therapy? •Of these patients, how many have received no active treatment in the past 6 months?

Date of Response: 04/12/2025
View Response: 10819.pdf

Freedom of Information Request Reference: 10818

Date Received: 10/11/2025

Summary:
1. Please provide Hemophilia A patient numbers broken down by: age, disease severity and treatment regimen (PPx denotes use for prophylaxis and OD denotes use on demand). I have proposed a format below to capture the relevant information. If data is not available by age breakdown, then please provide aggregated total in the yellow highlighted column: July through September 2025 Age Brand name (scientific) 0-12 years 13+ Mild Moderate Severe Mild Moderate Severe PPx OD PPx OD PPx OD PPx OD PPx OD PPx OD Hemlibra (emicizumab) Altuvoct (giroctocogene fitelparvovec) Esperoct (turoctocog alfa pegol) Elocta (efmoroctocog alfa) Advate (octocog alfa) Kovaltry (octocog alfa) Iblias (octocog alfa) Refacto AF (moroctocog alfa) Xyntha (moroctocog alfa) NovoEight (turoctocog alfa) Nuwiq (simoctocog alfa) Vihuma (simoctocog alfa) Inhibitor patients 2. For Hemlibra-treated Hemophilia A Inhibitor patients, please indicate the number of patients by age group and dosing frequency for Q3’25 (July–September 2025). If data is not available by age breakdown then please provide aggregated total: Age group (Hemophilia A inhibitor patients) Once weekly Every 2 weeks Every 4 weeks 0-12 years 13+ years Total Non-inhibitor patients 3. For Hemlibra-treated Hemophilia A non-inhibitor patients, please indicate the number of patients by age group and dosing frequency for Q3’25 (July–September 2025). If data is not available by age breakdown then please provide aggregated total: Age group (Hemophilia A non-inhibitor patients) Once weekly Every 2 weeks Every 4 weeks 0-12 years 13+ years Total

Date of Response: 05/12/2025
View Response: 10818.pdf

Freedom of Information Request Reference: 10817

Date Received: 05/11/2025

Summary:
I have read the reply but I think I am entitled to the information as it relates to me as the driver of the vehicle in question. According to the Telematics Guidance Document for users of NHLS Vehicles, Traffilog stores all recorded information from the initial go-live date. All users have the right to request, via their line manager, a copy of all information on their own stored data. Where stored data is not relevant to a member of staff, it will not be shared in any circumstances. Information recorded and stored by the telematics systems will be available and published in an anonymised format should NHSL receive a Freedom of Information request. It looks to me that I am entitled to the information I have requested as I was the driver of said vehicle. I look forward to your reply.

Date of Response: 28/11/2025
View Response: 10817.pdf

Freedom of Information Request Reference: 10816

Date Received: 06/11/2025

Summary:
Please provide the following information relating to your organisation’s use of temporary agency staffing. 1. Neutral Vend / Master Vend Do you use a Neutral Vend (NV) or Master Vend (MV) supplier for the following staff groups? If yes, please complete: Staff Group Supplier Name Contract Expiry Date Medical Allied Health Professionals (AHPs) Non-Medical, Non-Clinical (NMNC) Nursing 2. Direct Engagement (DE) Do you use a Direct Engagement supplier for any of the following staff groups? If yes, please complete: Staff Group DE Provider Contract Expiry Date % of Agency Spend via DE Medical Allied Health Professionals (AHPs) Non-Medical, Non-Clinical (NMNC) 3. Agency Spend (Most Recent Financial Year) Please provide total agency spend (worker pay & agency commission only): Staff Group Total Spend (£) Medical Allied Health Professionals (AHPs) Non-Medical, Non-Clinical (NMNC) Nursing 4. Agency Hours (Most Recent Financial Year) If you can access this information, please provide the total number of agency worker hours: Staff Group Total Hours Worked Medical Allied Health Professionals (AHPs) Non-Medical, Non-Clinical (NMNC) Nursing 5. Contract Management For any Neutral Vend, Master Vend, or Direct Engagement contracts in place, please provide: • Name of lead contact/responsible officer: • Job title: • Email address:

Date of Response: 28/11/2025
View Response: 10816.pdf

Freedom of Information Request Reference: 10815

Date Received: 10/11/2025

Summary:
Can I request, broken down by the calendar years 2019, 2020, 2021, 2022, 2023, 2024 and 2025 (most recent data): 1. How many midwifery shifts have gone unfilled after being put out for agency or bank cover, broken down by position. 2. How many obstetrics shifts have gone unfilled after being put out for locum cover, broken down by position (e.g. consultant, resident doctor).

Date of Response: 05/12/2025
View Response: 10815.pdf

Freedom of Information Request Reference: 10814

Date Received: 10/11/2025

Summary:
1. What was the percentage mark-up on the sale of sugar-sweetened beverages, confectionery, cakes, biscuits and similar items that were sold by your health board to patients, staff, and the public? 2. What was the profit made by your health board as a result of selling those items defined above?

Date of Response: 05/12/2025
View Response: 10814.pdf

Freedom of Information Request Reference: 10813

Date Received: 07/11/2025

Summary:
Request in relation to CCTV footage.

Date of Response: 07/11/2025
View Response: 10813.pdf

Freedom of Information Request Reference: 10812

Date Received: 07/11/2025

Summary:
How many formal complaints of bullying were made by midwives, consultant obstetricians, maternity care assistants, or other staff members working in the labour ward at the Royal Infirmary of Edinburgh in each calendar year from 2019 to 2025 (to date). How many formal complaints of bullying were made by other NHS staff departments at the Royal Infirmary of Edinburgh from 2019 to 2025 (to date). For example, break it down by A&E, paediatrics, etc.

Date of Response: 08/12/2025
View Response: 10812.pdf

Freedom of Information Request Reference: 10811

Date Received: 07/11/2025

Summary:
Please provide details of roles (role title and reporting structure), including information relating to Agenda For Change bandings as well as copies of any job descriptions. Please be advised I am not looking for personal details relating to post holders, such as the names of any individual staff members. Could you please confirm, for each post, the source of funding e.g. funded by internal budgets (and which budget e.g. medical), funded by Scottish Government etc.

Date of Response: 05/12/2025
View Response: 10811.pdf

Freedom of Information Request Reference: 10810

Date Received: 06/11/2025

Summary:
1. Temporary Staffing Agency Spend (1st June 2025 – 31st October 2025) • The total spend on agency Mental Health Nurses (including both inpatient and community roles such as CPNs), broken down by Band (2, 3, 5, 6, 7) excluding VAT: Band Jun-25 Jul-25 Aug-25 Sep-25 Oct-25 • The total hours filled by agency Mental Health Nurses (including both inpatient and community roles such as CPNs) Band Jun-25 Jul-25 Aug-25 Sep-25 Oct-25 2. Agency Supplier Information For each agency currently supplying Mental Health Nurses (Bands 2, 3, 5, 6, 7), please provide: a. Agency Name b. Agreed Charge Rates (total hourly cost to the Trust) for each Band c. Total Hours Supplied by each agency, broken down by Band, for the period 1st June 2025 – 31st October 2025. 3. Temporary Staffing Management Contacts • The department or team responsible for managing agency Mental Health Nurses (e.g., Workforce Planning, HR, Medical Staffing) • If available, a general contact phone number &/or email for workforce enquiries • If available, a contact name for Temporary staffing manager/lead and email

Date of Response: 11/12/2025
View Response: 10810.pdf

Freedom of Information Request Reference: 10809

Date Received: 06/11/2025

Summary:
In the period 1st August 2025 to 31st October 2025 please provide a breakdown of: • Total trust spend with framework agencies for locum doctors Please provide a further breakdown for locum doctors by: • Spend per grade • Spend per specialty • Spend per agency name  In the period 1st August 2025 to 31st October 2025 please provide a breakdown of: • Total trust spend with off-framework agencies for locums doctors Please provide a further breakdown for locum doctors by: • Spend per grade • Spend per specialty • Spend per agency name  In the period 1st August 2025 to 31st October 2025 please provide a breakdown of: • Total trust spend with the internal trust bank or associated external provider for locum doctors Please provide a further breakdown for locum doctors by: • Spend per grade • Spend per specialty • Spend per internal or associated external provider Please confirm your allocated budget for agency locum doctors for the period 1st August 2025 to 31st October 2025 Please confirm the name of the framework used for the supply of locum doctors in your trust.

Date of Response: 04/12/2025
View Response: 10809.pdf

Freedom of Information Request Reference: 10808

Date Received: 06/11/2025

Summary:
I am requesting the following from the Financial Year 2024/25: 1. The a) number of individuals receiving prescriptions, b) the number of prescriptions issued and c) the total cost of the prescriptions issued, for food products. 2. The a) number of individuals receiving prescriptions, b) the number of prescriptions issued and c) the total cost of the prescriptions issued, for weight loss drugs (including pills and injections).

Date of Response: 05/12/2025
View Response: 10808.pdf

Freedom of Information Request Reference: 10807

Date Received: 05/11/2025

Summary:
Q1. How many early-stage (non-metastatic or Stages 1-3) non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with: • Atezolizumab (Tecentriq) • Durvalumab (Imfinzi) • Nivolumab (Opdivo) • Pembrolizumab (Keytruda) • Chemotherapy • Radiotherapy • Chemotherapy AND Radiotherapy • Osimertinib Q2. How many patients has your trust treated in the last 3 months with Pembrolizumab for stage II Melanoma?

Date of Response: 04/12/2025
View Response: 10807.pdf

Freedom of Information Request Reference: 10806

Date Received: 05/11/2025

Summary:
Medical records / Digital Forms / Storage 1. Have you yet to start, partly started or completed scanning your medical records? 2. If started or completed, was this handled in-house or by an external company? If yes, please name the supplier 3. Have you digitalised all your forms and are running a PiP (Paperless in Patient) approach (from the point of patient presentation to them leaving are all patient records digitalised)? 4. If you are not using a PiP approach, do you scan your end of episode material? 5. Do you store medical records on site or is this handled off site by an external company? If yes, please name supplier 6. Do you use a digital HR staff onboarding and administration system that interfaces with ESR to support HR processes and workflows? Finally, who at the Trust is responsible for these arrangements?

Date of Response: 27/11/2025
View Response: 10806.pdf

Freedom of Information Request Reference: 10805

Date Received: 05/11/2025

Summary:
Print Room 1. Do you have a print room equipped with one/more high-speed production device/s to handle large volume printing? 2. Is this run by your own staff or outsourced to a third-party provider? 3. If run internally, how many full-time equivalent (FTE) run this facility? 4. Number of devices & model type/s? 5. Name of incumbent supplier? 6. Contract start / end date and length of any option to extend? 7. If outsourced, please advise contract start / end date and length of any option to extend? 8. Was this contract awarded through a framework? If yes, which one used? 9. Annual spend (ex VAT) covering equipment & staff costs or total outlay if this service is outsourced External Print 1. Do you outsource any print requirement to an external supplier/s (for example to print forms, booklets, leaflets, manuals, posters, banners etc)? 2. Name of incumbent supplier/s? 3. If this arrangement provided under contract, please advise start / end date and length of any option to extend? 4. Was this contract awarded through a framework? If yes, which one used? 5. Alternatively, was this awarded through a DPS arrangement? 6. Annual spend (ex VAT) for this service over the past 12 months? Mail Room (Inbound and/or Outbound) 1. Do you have your own in-house Mail Room operation? 2. If yes, how is the service run - physical or digital mail distribution? 3. Is this run by your own staff or outsourced to a third-party provider? 4. If run by your own staff, how many full-time equivalent (FTE) staff run this facility? 5. If outsourced, please advise name of current provider, contract start / end date and length of any option to extend? 6. Was this contract awarded through a framework? If yes, which one used? 7. Annual spend (ex VAT) covering running and staff costs or total outlay if this service outsourced? 8. Do you use a Hybrid Mail service as part of your patient communications approach? 9. If yes, please (a) name supplier (b) contract start / end date (c) framework through which this awarded? Finally, who at the Health Board is responsible for these arrangements?

Date of Response: 11/12/2025
View Response: 10805.pdf

Freedom of Information Request Reference: 10804

Date Received: 05/11/2025

Summary:
• The number of people currently being prescribed methadone by the NHS as of 5 November 2025. • The number of people who were being prescribed methadone on 5 November in each of the years 2021, 2022, 2023, and 2024. For example, X many people were being prescribed methadone on 5 November 2024, etc. If this is not possible, please instead provide it for the calendar year overall. • The cost to the NHS of prescribing methadone in each calendar year 2021, 2022, 2023, 2024, and 2025 to 5 November 2025.

Date of Response: 04/12/2025
View Response: 10804.pdf

Freedom of Information Request Reference: 10803

Date Received: 05/11/2025

Summary:
Please provide the data for the months of August 2025, September 2025, and October 2025 covering the following staff groups: • Midwives • Paediatric Nurses • Neonatal Intensive Care Unit (NICU) Nurses For each of these three months, please provide: 1. Total number of agency hours worked for each staff group. 2. Total agency spend (£) for each staff group. 3. Average charge rate (£ per hour) paid for each staff group.

Date of Response: 01/12/2025
View Response: 10803.pdf

Freedom of Information Request Reference: 10802

Date Received: 05/11/2025

Summary:
I would like to submit a Freedom of Information (FOI) request for the following data for Western General Hospital relating to Pompe disease for the period 1 July 2025 to 30 September 2025. For reference, Pompe disease may be coded under: * ICD-10: E74.0 (Glycogen storage disease), or more specifically noted as Acid Maltase Deficiency / Pompe disease * SNOMED CT Concept ID: 86651009 - Glycogen storage disease type II (Pompe disease) If exact matches are unavailable, please provide the nearest equivalent coding used by your Trust and specify the codes applied. Table 1 - Patients Treated and Diagnosed (Jul-Sep 2025)) Product Number of Patients Treated Number of Patients Diagnosed with Pompe (ICD-10 E74.0 / SNOMED 86651009) Avalglucosidase Alfa (Nexviazyme) Alglucosidase Alfa (Myozyme) Cipaglucosidase Alfa + Miglustat (Pombiliti) Table 2 - Patients Treated and Volume Used (Jul-Sep 2025) Product Volume Used (IUs or mg) Avalglucosidase Alfa (Nexviazyme) Alglucosidase Alfa (Myozyme) Cipaglucosidase Alfa + Miglustat (Pombiliti) Table 3 - New Patients Treated by Product (Jan-Mar 2025) Product July 2025 August 2025 September 2025 Avalglucosidase Alfa (Nexviazyme) Alglucosidase Alfa (Myozyme) Cipaglucosidase Alfa + Miglustat (Pombiliti) Table 4- Patients Treated by Age Group and by Product (Jul-Sep 2025) Product Age Group Number of patients treated Avalglucosidase Alfa (Nexviazyme) 0-11 12-17 18+ Alglucosidase Alfa (Myozyme) 0-11 12-17 18+ Cipaglucosidase Alfa + Miglustat (Pombiliti) 0-11 12-17 18+ Table 5: Naïve (New Start) and Switch Patients by Product (Jul-Sep 2025) Product Number of Naïve (New Start) Patients Number of Patients Switching To this Product Number of Patients Switching From this Product Avalglucosidase Alfa (Nexviazyme) Alglucosidase Alfa (Myozyme) Cipaglucosidase Alfa + Miglustat (Pombiliti)

Date of Response: 07/11/2025
View Response: 10802.pdf

Freedom of Information Request Reference: 10801

Date Received: 05/11/2025

Summary:
1. The number of unique patients with a recorded diagnosis of Primary Immunodeficiency (PID) in Q3'25(July, August, and September 2025) a. Of these PID patients, what is the number of PID patients treated with Immunoglobulin in Q3'25(July, August, and September 2025)If possible, segment patients by brand used e.g 5 patients on Cuvitru b. How of these Ig treated PID patients are naïve (new starts) in Q3'25(July, August, and September 2025)? 2. The number of unique patients with a recorded diagnosis of Secondary Immunodeficiency (SID) in Q3'25(July, August, and September 2025) a. Of these SID patients, what is the number of SID patients treated with Immunoglobulin Q3'25(July, August, and September 2025) If possible, segment patients by brand used? b. How of these Ig treated SID patients are naïve (new starts) in Q3'25(July, August, and September 2025)? 3. The number of unique patients with a recorded diagnosis of Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) in Q3'25(July, August, and September 2025) a. Of these SID patients, what is the number of CIDP patients treated with Immunoglobulin Q3'25(July, August, and September 2025) If possible, segment patients by brand used? b. How of these Ig treated CIDP patients are naïve (new starts) in Q3'25(July, August, and September 2025)? 4. Definition: (ICD Codes) For reference, the following ICD-10 codes apply to the indications listed above: Primary Immunodeficiency (PID): D80 (Immunodeficiency with predominantly antibody defects) Secondary Immunodeficiency (SID):  • D84.81 (Immunodeficiency due to conditions classified elsewhere)  • D84.821 (Immunodeficiency due to drugs)  • D84.822 (Immunodeficiency due to external causes)  • D84.9 (Immunodeficiency, unspecified) Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP): G61.8 (Other inflammatory polyneuropathies) 5. The number of immunoglobulin vials/volume in grams distributed to NHS Lothian in each month for July, August, and September 2025, broken down by product (see below). I would also like to request the number of patients NHS Lothian by brand if available * Vigam * Flebogamma DIF * Gammaplex * Gamunex-C * Octagam * Gamten * Kiovig * Intratect * Privigen * Iqymune * Gammanorm * Subcuvia * Subgam * Hizentra * Hyqvia * Cuvitru * Panzyga * Xembify * Cutaquig * Yimmugo • Vyvgart (Efgartigimod) (if available)

Date of Response: 04/12/2025
View Response: 10801.pdf

Freedom of Information Request Reference: 10800

Date Received: 04/11/2025

Summary:
1. How much has been incurred to date in relation to the planned National Treatment Centre in your health board, which is currently paused 2. In relation to Q1, how much has been incurred in each of the following financial years: 2024/25 and 2025/26 (most recent)

Date of Response: 27/11/2025
View Response: 10800.pdf

Freedom of Information Request Reference: 10799

Date Received: 04/11/2025

Summary:
1. Can you confirm if your health board carries out any training related to diversity, equality, and inclusion matters? 2. Please can you provide a breakdown of what the training in (1): a. Involves b. What subjects/topics/module the training relates to c. How much time is spent on each subject/topic/module d. The cost of each module 3. Please can you outline who is required to take this training? 4. What is the total cost of this training?

Date of Response: 03/12/2025
View Response: 10799.pdf

Freedom of Information Request Reference: 10798

Date Received: 04/11/2025

Summary:
1. Please could you supply the name, email address and telephone number of the commissioner with responsibility for packages of complex home care funded by NHS Scotland for (a) adults aged 18+ and (b) children aged 0-18 years old. 2. Please provide the number of people in receipt of complex home care packages funded by NHS Scotland (all active packages during the year including those which started prior) for (a) adults aged 18+ and (b) children aged 0-18 years old. 3. Please provide the total number of complex home care hours funded by NHS Scotland delivered for adults aged 18+. 4. Please provide the Health Board’s total gross expenditure on NHS-funded complex home care packages for adults aged 18+. 5. Please provide the Health Board’s total gross expenditure on NHS-funded complex home care packages for (a) adults aged 18+ and (b) children aged 0-18 years old. 6. Please provide the lowest, mean and highest hourly rate for NHS-funded complex home care packages for adults aged 18+ for 2020/21 to 2023/24, as well as a current snapshot. 7. Please provide the lowest, mean and highest weekly fee for NHS-funded complex home care packages for children aged 0-18 for 2020/21 to 2023/24, as well as a current snapshot. 8. Please provide a list of the top 10 providers who received the greatest amount of funding from NHS-funded complex home care packages. Please provide data for the last financial year 2023/24 for both (a) adults aged 18+ and (b) children aged 0-18 years old. i. For each provider, please provide the number of NHS-funded complex home care packages in 2023/24 (all active packages during the year including those which started prior). ii. For each provider, please provide total expenditure in 2023/24 related to NHS-funded complex home care packages.

Date of Response: 03/12/2025
View Response: 10798.pdf

Freedom of Information Request Reference: 10797

Date Received: 04/11/2025

Summary:
How many ovarian cancer patients (any stage) have been treated in the last 3 months with: Paclitaxel in combination with a platinum-based compound Platinum-based therapy alone (cisplatin or carboplatin) Bevacizumab in combination with paclitaxel and carboplatin Olaparib Olaparib + Bevacizumab Niraparib Rucaparib Does your trust participate in any clinical trials for the treatment of ovarian cancer? If so, please provide the name of each trial along with the number of patients taking part?

Date of Response: 27/11/2025
View Response: 10797.pdf

Freedom of Information Request Reference: 10796

Date Received: 04/11/2025

Summary:
I’m looking for information about maternity and neonatal services offered by your health board. Can you please provide the following data? 1. How many deaths of mothers and/or babies have been recorded by obstetric, midwifery, and/or home birth services within your health board each year for the last 10 years? 2. Of those deaths, how many have resulted in internal investigations? 3. What were the outcomes of those investigations? 4. How much has your health board spent settling negligence claims relating to obstetric care each year for the last 10 years?

Date of Response: 08/12/2025
View Response: 10796.pdf

Freedom of Information Request Reference: 10795

Date Received: 30/10/2025

Summary:
The average waiting times for CT scans undertaken where there is a suspected perforation at (i) Western General Hospital, Crewe Road South, Edinburgh (ii) Royal Infirmary of Edinburgh, 51 Little France Crescent, Old Dalkeith Road, Edinburgh between April and October 2021.

Date of Response: 27/11/2025
View Response: 10795.pdf

Freedom of Information Request Reference: 10794

Date Received: 30/10/2025

Summary:
We want to know how many ACS cases have occurred on elective (and non elective) orthopaedic wards in RIE in the recent past (approximately 10 years)? We don't want this data to undermine needs for training improvements - rather it should be used to clarify the lack of experience staff have with this rare but highly consequential complication, and therefore emphasise the need for regular training to keep relevant skills sharp.

Date of Response: 27/11/2025
View Response: 10794.pdf

Freedom of Information Request Reference: 10793

Date Received: 04/11/2025

Summary:
1. Actions Taken in Response to the PPSG Letter What steps has NHS Lothian taken in response to the requests outlined in the PPSG letter, specifically: • Distribution of information about PANS and PANDAS to GP practices. • Circulation of this information to paediatric units. 2. Recognition of Updated Guidance Does NHS Lothian recognise that the 2023 PANS PANDAS Steering Group Statement supersedes the 2021 BPNA Consensus Statement? 3. Clinical pathways and referral options. The Cabinet Secretary stated that there are multidisciplinary services for PANS and PANDAS currently available in Glasgow and Edinburgh. Please confirm details of these services within NHS Lothian including: • Referral pathways • Eligibility criteria • Whether referrals are accepted from other NHS Boards across Scotland

Date of Response: 04/12/2025
View Response: 10793.pdf

Freedom of Information Request Reference: 10792

Date Received: 04/11/2025

Summary:
Please provide recorded information (such as policies, protocols, terms of reference, or meeting minutes) held by your Board or by any regional or national Sarcoma Multi-Disciplinary Team (MDT) to which your Board contributes. ________________________________________ 1. Treatment Consistency Across Sarcoma Typologies Please provide any recorded policy, protocol, guidance, or minutes confirming whether radiation-induced sarcomas are treated according to causation (i.e. classified as one group for treatment purposes) or according to histological typology/subtype (e.g. angiosarcoma, leiomyosarcoma, spindle cell sarcoma, etc.). If no explicit policy exists, please provide any recorded correspondence or clinical governance paper where this distinction is discussed. ________________________________________ 2. Application of Cahan’s Criteria and Field Geometry Please provide any recorded guidance, standard operating procedure, or MDT minutes that clarify: a) Whether the terms “arising in” and “occurring in” a prior radiation field are treated as interchangeable in diagnostic discussions; and b) Whether the distance between the tumour’s epicentre and the edge of the prior radiation field is routinely measured or recorded—especially where the tumour later extends into a previously irradiated area. Include any imaging, physics, or radiotherapy-planning documentation addressing this assessment. ________________________________________ 3. Reconciliation of Prior and Proposed Radiation Fields Please provide any recorded policy, guidance, or meeting template confirming whether previous radiation fields are routinely reconciled with proposed radiation fields at sarcoma MDT meetings or during radiotherapy planning. If this check is formalised (for example as a standing agenda item or pre-planning step), please provide the relevant terms of reference, procedure, or meeting record. ________________________________________ 4. Constitution of the Sarcoma MDT Please provide the current terms of reference, membership list, or operating procedure for your Sarcoma MDT, indicating: • Which professional disciplines are core members required to attend each meeting (e.g. surgery, clinical oncology, medical oncology, pathology, radiology, nursing). • Whether attendance by a consultant surgeon is mandatory for quoracy. • Whether a departmental construct such as “Special Oncological Services (excluding surgery)” exists within your Board’s cancer governance structure, and, if so, how its remit interacts with surgical departments in MDT decision-making.

Date of Response: 08/12/2025
View Response: 10792.pdf

Freedom of Information Request Reference: 10791

Date Received: 03/11/2025

Summary:
In every year since 2020/21, in maternity units in your health board, what is: 1. The average time it has taken for stillbirth reports to be submitted after the death? 2. The longest time it has taken for stillbirth reports to be submitted after the death?

Date of Response: 27/11/2025
View Response: 10791.pdf

Freedom of Information Request Reference: 10789

Date Received: 03/11/2025

Summary:
In every year since 2020/21, how many shifts in maternity units in your health board have seen a reduced availability of midwives (a) by up to 50% and (b) of more than 50%?

Date of Response: 16/12/2025
View Response: 10789.pdf

Freedom of Information Request Reference: 10780

Date Received: 31/10/2025

Summary:
Re FOI 10643, are you aware of why the number of people who have accessed minor injuries in Edinburgh has been stable since 2019 while the number accessing it in East Lothian has fallen by two thirds in the same period?

Date of Response: 05/12/2025
View Response: 10780.pdf

Freedom of Information Request Reference: 10770

Date Received: 30/10/2025

Summary:
1. As at 30 September 2025, what is the number of medical consultant posts (all consultants regardless of specialty including NHS and honorary) in your board by WTE for the following (please note that all posts should be counted under ONE category only): a. posts occupied by a permanent consultant b. newly-created posts which have not yet been advertised c. vacant posts according to the ISD definition (“a post which has been cleared for advert after being through the redeployment process (internal or external advert) and remains a vacancy until an individual starts in the post”) d. vacant posts which are awaiting approval for recruitment e. posts which although currently unfilled are not under active recruitment, e.g. where a previous recruitment exercise has been unsuccessful f. all posts occupied by a locum consultant (including consultants re-engaged as locums who previously held a permanent post and those locum consultants employed via an agency) g. posts that have been recruited to but applicant not yet in post (e.g. deferred start due to pending CCT) h. The number of consultants that are on fixed term contracts i. other (please be specific) 2. As of 30 September 2025, how many of the posts listed under iii-viii above have not been occupied by a permanent substantive post holder since 31 March 2025? 3. As of 30 September 2025, what is the number of SAS (Specialty doctors, Specialists, Associate Specialists or staff grades) doctors in your board by WTE for the following (please note that all posts should be counted under ONE category only): a. posts occupied by a permanent SAS doctor b. newly created posts which have not yet been advertised (including new Specialist posts) c. vacant posts according to the definition “a post which has been cleared for advert after being through the redeployment process (internal or external advert) and remains a vacancy until an individual starts in the post” d. vacant posts which are awaiting approval for recruitment e. posts which although currently unfilled are not under active recruitment, e.g. where a previous recruitment exercise has been unsuccessful f. all posts occupied by a locum SAS doctor (including those locum specialty doctors employed via an agency) g. posts that have been recruited to but applicant not yet in post h. The number of SAS doctors on fixed term contracts i. other (please be specific) 4. As of 30 September 2025, how many of the posts listed under iii – viii above have not been occupied by a permanent substantive post holder since 31 March 2025?

Date of Response: 16/12/2025
View Response: 10770.pdf

Freedom of Information Request Reference: 10738

Date Received: 21/10/2025

Summary:
1. How long approximately is the wait list (e.g. number of weeks) to obtain an assessment by the CMHT and would this be by a consultant psychiatrist or their specialist trainee? 2. Are there criteria used to accept a rereferral onto your Community Mental Health Teams to have a care co-ordinator and provide treatment? If you have criteria, please can you supply them? 3. How long approximately is the wait list to obtain (a) a psychological assessment and then (b) how long is wait for CBT for OCD/BDD in secondary care (e.g. number of weeks)? 4. What is the documented or expected care pathway (e.g. do they have to be seen first by the CMHT and then referred by the CMHT for secondary care psychological therapies or can the referral be done directly by the Talking Therapies or GP for example)? 5. Do your policies or procedures indicate that any alternatives offered to CBT with ERP, for people in the above scenario, e.g. a different type of psychological therapy? 6. Has your team made a referral to tertiary services for OCD/BDD in the last 5 years a) under the Highly Specialised Service stream of funding or b) under local funding?

Date of Response: 05/12/2025
View Response: 10738.pdf

Freedom of Information Request Reference: 10729

Date Received: 21/10/2025

Summary:
We aim to evaluate your hospital’s current statistics and repeat this in 1-2 years’ time to evaluate impact from our project. We therefore request the following information and would appreciate your earliest response. 1. What is the annual number of patients you see in your unit with an early pregnancy complication? 2. How many patients were diagnosed as an ectopic pregnancy? 3. How many patients were treated as a pregnancy of unknown location? 4. Of the PUL group, how many patients went on to be confirmed as an ectopic pregnancy? 5. Number of reported patient safety incidents related to ectopic pregnancy? 6. For each incident, please specify degree of harm: • No harm • Near miss • Low • Moderate • Severe 7. For each moderate/severe incident, please specify details (e.g. late diagnosis, haemorrhage, etc). 8. How many moderate/severe incidents went on to be declared as a serious incident? 9. What was the learning for the serious incidents if any? Please note that we only require the information for the period 01 January 2023 to 01 January 2024

Date of Response: 19/12/2025
View Response: 10729.pdf

Freedom of Information Request Reference: 10715

Date Received: 16/10/2025

Summary:
1. What is the total size of the maintenance backlog, as at 1 October 2025 (or most recent)? Please provide the estimated value of the work to be completed in pounds sterling (£) as well as a breakdown of what work is outstanding, and the cost associated with undertaking that work. 2. Please also provide the total size of the maintenance backlog in pounds sterling (£) at the end of each financial year from 2019/20 to 2024/25.

Date of Response: 05/12/2025
View Response: 10715.pdf

Freedom of Information Request Reference: 10709

Date Received: 15/10/2025

Summary:
I would like to request the following information: 1. For each month (or week, if available) of the current calendar year (2025), please provide details of when the Birth Centre at the Royal Infirmary of Edinburgh has been: o Open and accepting admissions, and o Closed or temporarily unavailable for admissions. 2. If available, please also include: o The total number of days (or hours) the Birth Centre has been closed in 2025 to date. o The reasons recorded for each closure (e.g., staffing shortages, capacity issues, maintenance, etc.).

Date of Response: 16/12/2025
View Response: 10709.pdf

Freedom of Information Request Reference: 10503

Date Received: 20/08/2025

Summary:
Can I request the following information for each calendar year from 2019 to 2025 (most recent): 1. The number of Antenatal Classes run a) per year b) per month in your health board? 2. The number of spaces in the Antenatal Classes each year? 3. The waiting list length for someone to gain access to an Antenatal Class?

Date of Response: 05/12/2025
View Response: 10503.pdf

Freedom of Information Request Reference: 10617

Date Received: 25/09/2025

Summary:
The total number of individual patients who were prescribed paracetamol in the calendar years 2020, 2021, 2022, 2023, 2024, and 2025 to 30 June. Break this down both by the form in which the paracetamol was prescribed (for example, capsules, gel, spray) and the cost to the NHS of buying and supplying the prescribed paracetamol in each year. The total number of individual patients who were prescribed ibuprofen in the calendar years 2020, 2021, 2022, 2023, 2024, and 2025 to 30 June. Break this down both by the form in which the ibuprofen was prescribed (for example, capsules, gel, spray) and the cost to the NHS of buying and supplying the prescribed ibuprofen in each year.

Date of Response: 11/11/2025
View Response: 10617.pdf

Freedom of Information Request Reference: 10788

Date Received: 03/11/2025

Summary:
Q1. How many patients were treated in October 2025 (or latest available month) by the Dermatology department with the following drugs: • Abrocitinib (Cibinqo) • Baricitinib (Olumiant) • Dupilumab (Dupixent) • Lebrikizumab (Ebglyss) • Omalizumab (Xolair) • Tralokinumab (Adtralza) • Upadacitinib (Rinvoq) • Nemolizumab (Nemluvio) Q2. How many patients were treated in October 2025 (or latest available month) by the Respiratory Medicine departments with the following drugs: • Benralizumab (Fasenra) • Dupilumab (Dupixent) • Mepolizumab (Nucala) • Omalizumab (Xolair) • Reslizumab (Cinqaero) • Tezepelumab (Tezspire)

Date of Response: 28/11/2025
View Response: 10788.pdf

Freedom of Information Request Reference: 10787

Date Received: 03/11/2025

Summary:
In every year since 2020/21, how many women have experienced (a) significant blood loss and (b) serious birth tears while receiving maternity care in your health board?

Date of Response: 27/11/2025
View Response: 10787.pdf

Freedom of Information Request Reference: 10786

Date Received: 03/11/2025

Summary:
On how many occasions did staff employed on maternity units in your health board report concerns relating to staffing levels or shortages in (a) 2020/21, (b) 2021/22, (c) 2022/23, (d) 2023/24 and (e ) 2024/25?

Date of Response: 27/11/2025
View Response: 10786.pdf

Freedom of Information Request Reference: 10785

Date Received: 03/12/2025

Summary:
1) Please provide the headcount of NHS managers employed by your health board who were not involved in any form of clinical work, for each year from 2007 and 2025. 2) Please provide the percentage of the total workforce made up by these managers for each year from 2007 to 2025. 3) Please provide the total gross annual cost of employing these managers for each year from 2007 to 2025.

Date of Response: 27/11/2025
View Response: 10785.pdf

Freedom of Information Request Reference: 10784

Date Received: 03/11/2025

Summary:
In accordance with freedom of information legislation, I would be grateful if you could comply with the following request: • For every year since 2020/21, please can you provide the number of complaints you have received made by (a) patients and (b) staff about maternity care provided in your board?

Date of Response: 02/12/2025
View Response: 10784.pdf

Freedom of Information Request Reference: 10783

Date Received: 03/11/2025

Summary:
May I ask for your board's current waiting list numbers for the following treatments, to the nearest date possible: 1. Diagnostic hysteroscopy 2. Resection/ablation of interuterine lesion (Truclear or Myosure) 3. Endometrial ablation (Novasure) 4. Hysterectomy Please categorise into outpatient/inpatient if applicable and where possible.

Date of Response: 27/11/2025
View Response: 10783.pdf

Freedom of Information Request Reference: 10782

Date Received: 03/11/2025

Summary:
1/ a) How many MRI scanners does the Trust own? b) And how many X-ray machines? 2/ Could I please have the manufacturer, model, and date of installation for each MRI scanner and X-ray machine. 3/ Details of any defective, unused, or written-off medical equipment over the past three years, and its location.

Date of Response: 01/12/2025
View Response: 10782.pdf

Freedom of Information Request Reference: 10781

Date Received: 03/11/2025

Summary:
Please tell me how many a) operations and b) appointments have been cancelled due to bad weather or broken heating in a) 2020-21, b) 2021-22, c) 2022-23, d) 2023-24, e) 2024-25. If you are unable to provide this information please provide a breakdown of reasons for a) operations and b) appointments being cancelled.

Date of Response: 27/11/2025
View Response: 10781.pdf

Freedom of Information Request Reference: 10779

Date Received: 31/10/2025

Summary:
• The number of full-time equivalent consultant psychiatrist posts in the health board, i.e. those occupied, vacant or occupied by a locum. • Of which the number a) occupied by a permanent appointee, b) occupied by a locum, and c) currently vacant.

Date of Response: 27/11/2025
View Response: 10779.pdf

Freedom of Information Request Reference: 10778

Date Received: 31/10/2025

Summary:
1. How much was spent by the authority on outsourced radiology reporting in the following two periods: - the financial year 2024/25 - the six months from 1st April 2025 to 30th September 2025 2. For each of these periods, please state the amount spent with each of the following suppliers - Everlight Radiology - Four Ways - Medica - Telemedicine Clinic (TMC) - Dulwich Medical Centre - Hexarad - Other (please provide the name or names) 3. Has the authority formally tendered these services within the past 5 years? 4. If the answer to 3 is yes, please provide the following information - When was the tender awarded - Was it awarded to a single supplier, and if so which - What is the duration of the contract, with optional extension periods - Was the contract split into lots, for example non urgent routine reporting, and urgent out of hours reporting 5. Which suppliers of radiology reporting services currently have bi-directional access to the authority's patient record systems to allow access to patient records and input of radiology reports. 6. Does the risk of cyber attack as a result of providing the access described in 5 appear on the trust risk register and what level of risk rating is it given 7. Is the trust able to split the spend stated in response to question 1 into: urgent reporting (such as the Medica Nighthawk service for A&E patients); and routine backlog reporting. If so, please provide this split

Date of Response: 27/11/2025
View Response: 10778.pdf

Freedom of Information Request Reference: 10777

Date Received: 31/10/2025

Summary:
Please can you provide me with the number of requests made for urgent or unplanned mental health support in your health board between 20th December and 6th January in every year since 2020/21.

Date of Response: 27/11/2025
View Response: 10777.pdf

Freedom of Information Request Reference: 10776

Date Received: 31/10/2025

Summary:
Please provide this information for each calendar year since 2019 to 2025 (most recent) 1. The number of patients who died in hospital while awaiting discharge after it was delayed 2. The number of patients 65 and over who died in hospital while awaiting discharge after it was delayed 3. The number of patients with dementia who died in hospital while awaiting discharge after it was delayed For points 1-3 please also state how many were delayed because they were waiting for health and social care reasons.

Date of Response: 27/11/2025
View Response: 10776.pdf

Freedom of Information Request Reference: 10775

Date Received: 31/10/2025

Summary:
Question 1. Does your health board have a general practice ‘risk register’ listing practices that are having problems with the recruitment partners, sessional doctors or locums for maternity or long term sickness, or any other reason? If yes, please provide a copy. Question 2. Does your health board have a general practice or health centre ‘risk register’ listing problems or concerns with premises/facilities/buildings.

Date of Response: 28/11/2025
View Response: 10775.pdf

Freedom of Information Request Reference: 10774

Date Received: 31/10/2025

Summary:
1. What was the total number of patients whose total time in accident and emergency, from arrival to their admission, transfer, or discharge, was 12 hours or more in the 2024-2025 financial year? 2. What percentage of patients whose total time in accident and emergency, from arrival to their admission, transfer, or discharge, was 12 hours or more, fell within the following age ranges in the 2024-2025 financial year: a) 0–4 b) 5–9 c) 10–14 d) 15–19 e) 20–24 f) 25–34 g) 35–44 h) 45–54 I) 55–64 j) 65–74 k) 75–84 l) 85 and over

Date of Response: 27/11/2025
View Response: 10774.pdf

Freedom of Information Request Reference: 10773

Date Received: 31/10/2025

Summary:
Please provide the total number of NHS staff absences recorded across your health board area during the Christmas fortnight (defined as 24 December to 6 January, inclusive) for each of the last five years (2020/21 to 2024/25). If available, please also include: • A breakdown by staff category (e.g. medical, nursing, allied health professionals, administrative/support staff). • The primary reasons for absence (e.g. sickness, annual leave, other). If projections or internal estimates are available for the forthcoming Christmas period (2025/26), please include these as well.

Date of Response: 28/11/2025
View Response: 10773.pdf

Freedom of Information Request Reference: 10772

Date Received: 30/10/2025

Summary:
A breakdown of the number of patients who were classified as a failed discharge in 2019, 2020, 2021, 2022, 2023, 2024 and 2025 (if this term is used) OR the number of patients who were discharged and then readmitted after 1 to 7 days with a breakdown for the same period.

Date of Response: 27/11/2025
View Response: 10772.pdf

Freedom of Information Request Reference: 10771

Date Received: 30/10/2025

Summary:
I am seeking information with regards to NHS Lothian Board Member attendance by Councillor representation from City of Edinburgh Council. 1. Who were the Council’s representative(s) from the period 01.08.2024 to present day? 2. What were the dates of the board meetings and what was the attendance record by representatives in answer 1. 3. How much has each representative been paid as a member of the NHS Lothian Board? 4. Has there been any communication on issues of attendance or non-attendance by the representatives in answer 1. 5. Any other relevant information available.

Date of Response: 27/11/2025
View Response: 10771.pdf

Freedom of Information Request Reference: 10769

Date Received: 30/10/2025

Summary:
To ask how many admissions there have been to hospitals in your area relating to the use of Performance and Image Enhancing Drugs (PIEDs). Could this cover the following financial years... 2024/25 2023/24 2022/23 2021/22 2020/21 If possible, could you break the instance down by type of PIED, and if possible could you provide the rough age group of patient.

Date of Response: 26/11/2025
View Response: 10769.pdf

Freedom of Information Request Reference: 10768

Date Received: 30/10/2025

Summary:
To ensure there is no misunderstanding, I have restated the original points below, with notes on the areas where further clarification would be helpful. ________________________________________ 1. Agenda item location Could you please confirm the exact meeting date and agenda item reference under which the decision to withdraw, reduce, or not fund relevant services was taken? If no other recorded information exists beyond the linked document, I would be grateful if this could be confirmed under Section 17. ________________________________________ 2. Exempt business Was this decision considered entirely within the public session, or was any element discussed under exempt business? If an exemption applied, could you please confirm the title of the item and the exemption category used, or confirm under Section 17 if this information is not held? ________________________________________ 3. Equality considerations The linked report refers to an Integrated Impact Assessment at Appendix 1. For clarity, could you confirm whether this assessment, or any associated Equality Impact Assessment or Fairer Scotland Duty assessment, contains reference to adult ADHD, adult autism, or neurodivergent adults in general? If no such material was prepared or considered, please confirm this under Section 17. If held elsewhere, please advise under Section 15. ________________________________________ 4. Decision clarity Could you please confirm in plain terms what decision was taken in relation to services used by adult ADHD and adult autism cohorts? If the decision related solely to third-sector grant-funded supports rather than clinical diagnostic pathways, I would be grateful if you could confirm that distinction, and identify any grants or funded programmes that related to these user groups.

Date of Response: 27/11/2025
View Response: 10768.pdf

Freedom of Information Request Reference: 10767

Date Received: 30/10/2025

Summary:
In connection with the Public Social Partnership (PSP) model referenced in the EIJB paper dated 1 November 2024, please provide the following recorded information: ________________________________________ 1. Funding and budgets The total funding allocated or planned for the PSP by year from 2023/24 onwards, including any internal budgets, envelopes, or recorded allocations for 2024/25 and 2025/26. ________________________________________ 2. Partners and agreements A list of partner organisations or service providers involved in the PSP, along with any service specifications, partnership agreements, or memoranda of understanding. ________________________________________ 3. Selection process and criteria Any documentation describing the criteria, scoring framework, or decision process used to determine which organisations were included in the PSP and at what funding level. ________________________________________ 4. Service coverage and mitigation Any recorded plan, briefing, or assessment explaining how the PSP intends to address impacts arising from the closure of the EIJB Grants Programme, particularly in relation to adult neurodivergent users such as those with ADHD or autism.

Date of Response: 27/11/2025
View Response: 10767.pdf

Freedom of Information Request Reference: 10766

Date Received: 30/10/2025

Summary:
Please provide the following recorded information held by NHS Lothian in relation to the Edinburgh Integration Joint Board (EIJB) decision of 1 November 2024 titled “Edinburgh Integration Joint Board Grants Programme and Public Social Partnership.” ________________________________________ 1. Projects and organisations A list of all grant-funded projects and organisations affected by the conclusion or transition of the EIJB Grants Programme, together with any service descriptions and client groups served, for 2023/24 and 2024/25. If this information is already published, please cite Section 25 and provide the exact page, appendix, or table reference. ________________________________________ 2. Adult ADHD and autism-related supports Any report, mapping document, or correspondence identifying which of those grants provided support to adult neurodivergent users, including those with ADHD or autism, together with the recorded 2023/24 and 2024/25 grant amounts. If no such record exists, please confirm under Section 17. ________________________________________ 3. Recorded impact assessment Any documentation, briefing, or analysis that identifies impacts on service users unable to access private support, such as effects on waiting lists, service continuity, or identified service gaps, arising from the closure or transition of these programmes. If none is held, please confirm under Section 17. ________________________________________ 4. Mitigation or transition arrangements Any recorded plans or correspondence describing interim, mitigation, or replacement arrangements for services previously accessed by adult ADHD and adult autism cohorts.

Date of Response: 27/11/2025
View Response: 10766.pdf

Freedom of Information Request Reference: 10765

Date Received: 30/10/2025

Summary:
Patient Attendance • How many patients in total have accessed the service in the last 12 months? What referral method to the service made up the contribution of all referrals? • HCP Referral (primary care) • HCP Referral (secondary care) • Patient Self-referral • Other Daily Interventions • How many patients were qualified to receive some sort of pharmacological intervention (aligned to NICE), regardless of whether they went on to receive treatment? • How many patients received pharmacological treatment? • For patients who did not receive pharmacological treatment, what were the top 3 reasons for a patient not receiving treatment? e.g.: Outside of treatment window, not eligible (NICE), watch & wait, symptoms not severe enough, late positive test result, etc. • For those patients that did receive treatment, what was their main underlying primary condition that qualified them to be eligible to receive treatment? o e.g. Solid Cancer, immune suppressed, renal disease, etc. Capacity • How many HCPs do you have within the COVID-19 service? • i.e. no. of prescribers, no. of additional staff, etc.

Date of Response: 26/11/2025
View Response: 10765.pdf

Freedom of Information Request Reference: 10764

Date Received: 30/10/2025

Summary:
• The mean, median and mode wait for a Lower Limb Orthopaedic outpatient consultation. • The longest recorded wait for a Lower Limb Orthopaedic outpatient consultation since 1 January 2023. • The mean, median and mode wait for a Lower Limb Orthopaedic inpatient consultation. • The longest recorded wait for a Lower Limb Orthopaedic inpatient consultation since 1 January 2023. • The mean, median and mode wait for knee replacement surgery. • The longest recorded wait for knee replacement surgery since 1 January 2023.

Date of Response: 21/11/2025
View Response: 10764.pdf

Freedom of Information Request Reference: 10763

Date Received: 30/10/2025

Summary:
Please provide the following information regarding the use of esketamine nasal spray (Spravato) for treatment-resistant depression (as accepted for use by the Scottish Medicines Consortium under SMC2258): 1) Service Availability • Does NHS Lothian currently provide esketamine (Spravato) treatment for TRD? • If yes: • Service name and clinical location(s) • Date the service started • Eligibility criteria / referral pathway • Number of patients treated per year since launch • Current waiting list length and expected wait time • Total annual cost or budget allocation (if recorded) 2) If not currently provided • Has NHS Lothian ever provided esketamine treatment? • If previously provided, please state: • Dates of operation • Patient numbers • Reason for withdrawal / cessation 3) Future plans • Does NHS Lothian plan to establish an esketamine service? • If yes, expected start date and delivery model 4) Cross-board options If NHS Lothian does not provide esketamine, which NHS boards (if any) it refers patients to for this treatment.

Date of Response: 27/11/2025
View Response: 10763.pdf

Freedom of Information Request Reference: 10762

Date Received: 29/10/2025

Summary:
I request the following information concerning the cancer medicine pembrolizumab (brand name Keytruda). 1. For each of the past 10 financial years (2014/15 to 2023/24, or the most recent 10-year period available), please provide top 10 medicines by total estimated cost for medicines positively appraised, prescribed or issued in all sectors. 2. For each of the past 10 financial years (2014/15 to 2023/24, or the most recent 10-year period available), please provide the total expenditure on Pembrolizumab (brand name Keytruda). 3. For each of the past 10 financial years (2014/15 to 2023/24, or the most recent 10-year period available), please provide the number of individual patients treated with Pembrolizumab. 4. For each of the six patients who were/have been on Pembrolizumab for the longest, what has it cost the Board per patient? 5. Please provide a list of all licensed indications for which Pembrolizumab is currently used within the Board. For each indication, please provide the year in which it was first licensed for use. 6. For each of the past 5 financial years (2019/20 to 2023/24, or the most recent 5-year period available), how many legal challenges or complaints have you had regarding Pembrolizumab and what was the nature of each of these? 7. For each of the past 10 financial years (2019/20 to 2023/24, or the most recent 10-year period available), how many adverse events, and separately, serious adverse events, have you had which reference Pembrolizumab?

Date of Response: 26/11/2025
View Response: 10762.pdf

Freedom of Information Request Reference: 10761

Date Received: 29/10/2025

Summary:
I would be grateful if you could tell me how many patients were treated by individual drugs from the dermatology, gastroenterology, and rheumatology departments (for any disease) for the three-month period specified within the question. Q1a - How many patients were treated with the following drugs from the following departments (for any disease) from the start of July 2025 to the end of September 2025? If Rheumatology cannot provide historic data, a snapshot of those currently being treated would be helpful. Please use the latest available 3 months if July to September is not available and specify which 3 months has been used. Drug Name Dermatology Gastroenterology Rheumatology Adalimumab Bimekizumab Brodalumab Certolizumab Pegol Deucravacitinib Etanercept Etrasimod Filgotinib Golimumab Guselkumab Infliximab (Biosimilars) Infliximab (Remicade) Ixekizumab Mirikizumab Ozanimod Risankizumab Secukinumab Tildrakizumab Tofacitinib Upadacitinib Ustekinumab Vedolizumab

Date of Response: 26/11/2025
View Response: 10761.pdf

Freedom of Information Request Reference: 10759

Date Received: 29/10/2025

Summary:
For each of the past five financial years, including this year to date, please provide: 1. The longest recorded time a patient has spent in an Accident and Emergency (A&E) department within your health board area. 2. The hospital where this occurred. 3. The reason for the delay, if this information is recorded.

Date of Response: 26/11/2025
View Response: 10759.pdf

Freedom of Information Request Reference: 10758

Date Received: 29/10/2025

Summary:
In each of the last 5 years, how many patients have been in hospital due to delayed discharge in the period between 22nd December to 4th January inclusive?

Date of Response: 26/11/2025
View Response: 10758.pdf

Freedom of Information Request Reference: 10757

Date Received: 29/10/2025

Summary:
How many babies were born with neonatal abstinence syndrome in your health board area in (a) 2024/25 and b) 2025/26 to date?

Date of Response: 13/11/2025
View Response: 10757.pdf

Freedom of Information Request Reference: 10756

Date Received: 28/10/2025

Summary:
I would like to request any policies and/or guidelines used in your the healthcare of infants who are intersex/have a difference or disorder of sexual development, or have ambiguous genitalia at birth (such as clitoromegaly, microphallus or other atypicality). If NHS Lothian does not have guidelines or policies relating to the above, please let me know.

Date of Response: 24/11/2025
View Response: 10756.pdf

Freedom of Information Request Reference: 10755

Date Received: 28/10/2025

Summary:
If a doctor works at the NHS and also with a private hospital, can they access medical records and use them for private patients.

Date of Response: 24/11/2025
View Response: 10755.pdf

Freedom of Information Request Reference: 10754

Date Received: 28/10/2025

Summary:
I would be grateful if you could provide the following data regarding agency temporary staffing spend within your Trust. I would be grateful if you could provide the following: Requested Information: 1. Temporary Staffing Agency Spend (1st July 2025 – 30th September 2025) o The total spend on agency Paediatrics Medical Locums, broken down by grade and month, excluding VAT: Grade July 25 August 25 September 25 Consultant £ £ £ Associate Specialist £ £ £ Staff Grade £ £ £ Specialty Doctor £ £ £ Specialist Registrar £ £ £ Registrar £ £ £ ST3+ £ £ £ ST1 - 2 £ £ £ SHO £ £ £ o The total hours filled by agency Paediatrics Medical Locums, broken down by grade and month: Grade July 25 August 25 September 25 Consultant Associate Specialist Staff Grade Specialty Doctor Specialist Registrar Registrar ST3+ ST1 - 2 SHO

Date of Response: 21/11/2025
View Response: 10754.pdf